Objective To explore the role of erythropoietin( EPO)in neurovirulent damages( NVD)caused by pa-clitaxel chemotherapy in patients with advanced ovarian cancers( AOC). Methods A total of 124 Ⅲ-Ⅳ stage AOC patients admitted to Center Hospital of Xiangyang from February 2009 to March 2012 were divided,according to receiving EPO treatment or not,into groups early EPO,advanced EPO,non-EPO. FACT/GO-NTX questionnaire was used to evaluate the neuroviru-lence of 3 groups. The neurovirulence,time of NVD appearance,accumulated paclitaxel were compared among 3 groups. NVDs compared between patients with different grades of anemia in EPO group. Results The incidences of NVD of groups early EPO, advanced EPO,non-EPO were 24. 4%(10/41),42. 5%(17/40),53. 5%(23/43),respectively,the difference was significant(H=6. 862,P =0. 032). There was difference in incidences of different grades of NVD among 3 groups(P <0. 05). There was difference in NVD incidence between patients with different grades of anemia in early EPO group( u =-3. 810,P<0. 05). The earliest time of neurovirulence occurrence was longer in early EPO group〔(12. 3 ± 2. 2) weeks〕than in groups advanced EPO〔(10. 7 ±1. 6)weeks〕,non-EPO〔(7. 7 ±1. 2)weeks,P<0. 05〕. The mean paclitaxel dosage was(785. 3 ± 67. 5) mg in early EPO group at earliest time of neurovirulence occurrence,higher than in groups ad-vanced EPO〔(511. 6 ± 61. 7) mg〕,non-EPO〔(354. 2 ± 47. 5) mg,P<0. 05〕. Conclusion EPO can reduce the NVD caused by paclitaxel chemotherapy in Ⅲ-Ⅳ AOC patients. Early use of EPO is of more remarkable effects.%目的：探讨促红细胞生成素（ EPO）对晚期（Ⅲ~Ⅳ期）卵巢癌经紫杉醇化疗后诱发的神经毒性损伤的保护作用。方法选取2009年2月-2012年3月襄阳市中心医院收治的Ⅲ~Ⅳ期卵巢癌患者124例，根据其是否接受EPO治疗及接受治疗的时间分为早期EPO组、晚期EPO组、非EPO组。根据癌症治疗功能评估/妇科肿瘤神经毒性问卷（ FACT/GOG-NTX问卷）评分对3组患者行神经毒性评估。比较3组患者神经毒性分级、最早出现神经毒性损伤的时间以及累积紫杉醇用量；比较早期EPO组不同贫血分级患者的神经毒性损伤分级。结果3组患者神经毒性分级间差异有统计学意义（ H=6.862，P=0.032）。早期EPO组不同贫血分级患者的神经毒性损伤分级间差异有统计学意义（u=-3.810，P <0.05）。早期 EPO 组发生神经毒性损伤最早时间〔（12.3±2.2）周〕长于晚期 EPO 组〔（10.7±1.6）周〕及非EPO组〔（7.7±1.2）周，P<0.05〕。早期EPO组最早发生神经毒性损伤时紫杉醇用量平均为（785.3±67.5） mg，高于晚期EPO组〔（511.6±61.7） mg〕及非EPO组〔（354.2±47.5） mg，P<0.05〕。结论 EPO能够有效减轻以紫杉醇为基础化疗的Ⅲ~Ⅳ期卵巢癌患者神经毒性，早期应用EPO效果更显著。
展开▼
